Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2010

01.01.2010 | Clinical trial

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

verfasst von: Elisabeth R. Garwood, Anjali S. Kumar, Frederick L. Baehner, Dan H. Moore, Alfred Au, Nola Hylton, Chris I. Flowers, Judy Garber, Beth-Ann Lesnikoski, E. Shelley Hwang, Olofunmilao Olopade, Elisa Rush Port, Michael Campbell, Laura J. Esserman

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study is to determine the biologic impact of short-term lipophilic statin exposure on in situ and invasive breast cancer through paired tissue, blood and imaging-based biomarkers. A perioperative window trial of fluvastatin was conducted in women with a diagnosis of DCIS or stage 1 breast cancer. Patients were randomized to high dose (80 mg/day) or low dose (20 mg/day) fluvastatin for 3–6 weeks before surgery. Tissue (diagnostic core biopsy/final surgical specimen), blood, and magnetic resonance images were obtained before/after treatment. The primary endpoint was Ki-67 (proliferation) reduction. Secondary endpoints were change in cleaved caspase-3 (CC3, apoptosis), MRI tumor volume, and serum C-reactive protein (CRP, inflammation). Planned subgroup analyses compared disease grade, statin dose, and estrogen-receptor status. Forty of 45 patients who enrolled completed the protocol; 29 had paired Ki-67 primary endpoint data. Proliferation of high grade tumors decreased by a median of 7.2% (P = 0.008), which was statistically greater than the 0.3% decrease for low grade tumors. Paired data for CC3 showed tumor apoptosis increased in 38%, remained stable in 41%, and decreased in 21% of subjects. More high grade tumors had an increase in apoptosis (60 vs. 13%; P = 0.015). Serum CRP did not change, but cholesterol levels were significantly lower post statin exposure (P < 0.001). Fluvastatin showed measurable biologic changes by reducing tumor proliferation and increasing apoptotic activity in high-grade, stage 0/1 breast cancer. Effects were only evident in high grade tumors. These results support further evaluation of statins as chemoprevention for ER-negative high grade breast cancers.
Literatur
1.
Zurück zum Zitat Beck P, Wysowski DK, Downey W et al (2003) Statin use and the risk of breast cancer. J Clin Epidemiol 56:280–285CrossRefPubMed Beck P, Wysowski DK, Downey W et al (2003) Statin use and the risk of breast cancer. J Clin Epidemiol 56:280–285CrossRefPubMed
2.
Zurück zum Zitat Boudreau DM, Yu O, Miglioretti DL et al (2007) Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomark Prev 16:416–421CrossRef Boudreau DM, Yu O, Miglioretti DL et al (2007) Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomark Prev 16:416–421CrossRef
3.
Zurück zum Zitat Cauley JA, McTiernan A, Rodabough RJ et al (2006) Statin use and breast cancer: prospective results from the Women’s Health Initiative. J Natl Cancer Inst 98:700–707PubMedCrossRef Cauley JA, McTiernan A, Rodabough RJ et al (2006) Statin use and breast cancer: prospective results from the Women’s Health Initiative. J Natl Cancer Inst 98:700–707PubMedCrossRef
4.
Zurück zum Zitat Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213–219CrossRefPubMed Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213–219CrossRefPubMed
5.
Zurück zum Zitat Eliassen AH, Colditz GA, Rosner B et al (2005) Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165:2264–2271CrossRefPubMed Eliassen AH, Colditz GA, Rosner B et al (2005) Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165:2264–2271CrossRefPubMed
6.
Zurück zum Zitat Farwell WR, Scranton RE, Lawler EV et al (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134–139CrossRefPubMed Farwell WR, Scranton RE, Lawler EV et al (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134–139CrossRefPubMed
7.
8.
Zurück zum Zitat Kwan ML, Habel LA, Flick ED et al (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109:573–579CrossRefPubMed Kwan ML, Habel LA, Flick ED et al (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109:573–579CrossRefPubMed
9.
Zurück zum Zitat Pocobelli G, Newcomb PA, Trentham-Dietz A et al (2008) Statin use and risk of breast cancer. Cancer 112:27–33CrossRefPubMed Pocobelli G, Newcomb PA, Trentham-Dietz A et al (2008) Statin use and risk of breast cancer. Cancer 112:27–33CrossRefPubMed
10.
Zurück zum Zitat Taylor ML, Wells BJ, Smolak MJ (2008) Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 17:259–268CrossRefPubMed Taylor ML, Wells BJ, Smolak MJ (2008) Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 17:259–268CrossRefPubMed
11.
Zurück zum Zitat Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278CrossRefPubMed Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278CrossRefPubMed
12.
Zurück zum Zitat Peto R, Emberson J, Landray M et al (2008) Analyses of cancer data from three ezetimibe trials. N Engl J Med 359:1357–1366CrossRefPubMed Peto R, Emberson J, Landray M et al (2008) Analyses of cancer data from three ezetimibe trials. N Engl J Med 359:1357–1366CrossRefPubMed
13.
Zurück zum Zitat Bonovas S, Filioussi K, Tsavaris N et al (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23:8606–8612CrossRefPubMed Bonovas S, Filioussi K, Tsavaris N et al (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23:8606–8612CrossRefPubMed
14.
Zurück zum Zitat Dale KM, Coleman CI, Henyan NN et al (2006) Statins and cancer risk: a meta-analysis. JAMA 295:74–80CrossRefPubMed Dale KM, Coleman CI, Henyan NN et al (2006) Statins and cancer risk: a meta-analysis. JAMA 295:74–80CrossRefPubMed
15.
Zurück zum Zitat Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120:833–843CrossRefPubMed Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120:833–843CrossRefPubMed
16.
Zurück zum Zitat Kumar AS, Benz CC, Shim V et al (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomark Prev 17:1028–1033CrossRef Kumar AS, Benz CC, Shim V et al (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomark Prev 17:1028–1033CrossRef
17.
Zurück zum Zitat Campbell MJ, Esserman LJ, Zhou Y et al (2006) Breast cancer growth prevention by statins. Cancer Res 66:8707–8714CrossRefPubMed Campbell MJ, Esserman LJ, Zhou Y et al (2006) Breast cancer growth prevention by statins. Cancer Res 66:8707–8714CrossRefPubMed
18.
Zurück zum Zitat Kotamraju S, Williams CL, Kalyanaraman B (2007) Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 67:7386–7394CrossRefPubMed Kotamraju S, Williams CL, Kalyanaraman B (2007) Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 67:7386–7394CrossRefPubMed
19.
Zurück zum Zitat Koyuturk M, Ersoz M, Altiok N (2007) Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 250:220–228CrossRefPubMed Koyuturk M, Ersoz M, Altiok N (2007) Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 250:220–228CrossRefPubMed
20.
Zurück zum Zitat Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed
21.
Zurück zum Zitat Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410CrossRefPubMed Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410CrossRefPubMed
22.
Zurück zum Zitat Hylton NM (1999) Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. Magn Reson Imaging Clin N Am 7:411–420, x Hylton NM (1999) Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. Magn Reson Imaging Clin N Am 7:411–420, x
23.
Zurück zum Zitat Port ER, Montgomery LL, Heerdt AS et al (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8:580–585CrossRefPubMed Port ER, Montgomery LL, Heerdt AS et al (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8:580–585CrossRefPubMed
24.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see comments]. J Natl Cancer Inst 90:1371–1388CrossRefPubMed Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see comments]. J Natl Cancer Inst 90:1371–1388CrossRefPubMed
25.
Zurück zum Zitat Vogel VG, Costantino JP, Wickerham DL et al (2002) Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 94:1504PubMed Vogel VG, Costantino JP, Wickerham DL et al (2002) Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 94:1504PubMed
26.
Zurück zum Zitat Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–2741CrossRefPubMed Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–2741CrossRefPubMed
27.
Zurück zum Zitat Gass M, Dawson-Hughes B (2006) Preventing osteoporosis-related fractures: an overview. Am J Med 119:S3–S11CrossRefPubMed Gass M, Dawson-Hughes B (2006) Preventing osteoporosis-related fractures: an overview. Am J Med 119:S3–S11CrossRefPubMed
28.
Zurück zum Zitat Hebert PR, Gaziano JM, Chan KS et al (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278:313–321CrossRefPubMed Hebert PR, Gaziano JM, Chan KS et al (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278:313–321CrossRefPubMed
29.
Zurück zum Zitat LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282:2340–2346CrossRefPubMed LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282:2340–2346CrossRefPubMed
30.
Zurück zum Zitat Wang CY, Liu PY, Liao JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14:37–44CrossRefPubMed Wang CY, Liu PY, Liao JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14:37–44CrossRefPubMed
31.
Zurück zum Zitat Collins R, Armitage J, Parish S et al (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757–767CrossRefPubMed Collins R, Armitage J, Parish S et al (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757–767CrossRefPubMed
32.
Zurück zum Zitat Collins R, Armitage J, Parish S et al (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016CrossRefPubMed Collins R, Armitage J, Parish S et al (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016CrossRefPubMed
33.
Zurück zum Zitat Endres M, Laufs U, Huang Z et al (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880–8885CrossRefPubMed Endres M, Laufs U, Huang Z et al (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880–8885CrossRefPubMed
34.
Zurück zum Zitat Laufs U, Liao JK (2000) Targeting Rho in cardiovascular disease. Circ Res 87:526–528PubMed Laufs U, Liao JK (2000) Targeting Rho in cardiovascular disease. Circ Res 87:526–528PubMed
35.
Zurück zum Zitat Laufs U, Marra D, Node K et al (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 274:21926–21931CrossRefPubMed Laufs U, Marra D, Node K et al (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 274:21926–21931CrossRefPubMed
36.
Zurück zum Zitat Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Investig 110:285–288PubMed Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Investig 110:285–288PubMed
37.
Zurück zum Zitat Liao JK (2002) Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 86:5–18CrossRefPubMed Liao JK (2002) Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 86:5–18CrossRefPubMed
38.
Zurück zum Zitat Liao JK (2004) Statin therapy for cardiac hypertrophy and heart failure. J Investig Med 52:248–253CrossRefPubMed Liao JK (2004) Statin therapy for cardiac hypertrophy and heart failure. J Investig Med 52:248–253CrossRefPubMed
39.
Zurück zum Zitat Liao JK, Bettmann MA, Sandor T et al (1991) Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 68:1027–1034PubMed Liao JK, Bettmann MA, Sandor T et al (1991) Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 68:1027–1034PubMed
40.
Zurück zum Zitat Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89–118CrossRefPubMed Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89–118CrossRefPubMed
41.
Zurück zum Zitat Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24F–33FCrossRefPubMed Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24F–33FCrossRefPubMed
42.
Metadaten
Titel
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer
verfasst von
Elisabeth R. Garwood
Anjali S. Kumar
Frederick L. Baehner
Dan H. Moore
Alfred Au
Nola Hylton
Chris I. Flowers
Judy Garber
Beth-Ann Lesnikoski
E. Shelley Hwang
Olofunmilao Olopade
Elisa Rush Port
Michael Campbell
Laura J. Esserman
Publikationsdatum
01.01.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0507-x

Weitere Artikel der Ausgabe 1/2010

Breast Cancer Research and Treatment 1/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.